Navigation Links
Transgenomic, Inc. Reports Second Quarter 2007 Results
Date:8/19/2007

ic variation and mutation analysis. Their offerings include systems, products, discovery and laboratory testing services to the academic and medical research, clinical laboratory and pharmaceutical markets in the fields of pharmacogenomics and personalized medicine. Specific offerings include WAVE(R) DHPLC Systems, related consumables and assay kits, cytogenetics automated systems, and Transgenomic Discovery and CLIA Lab Services. Transgenomic Discovery and Lab Services utilize their technology and expertise to provide a menu of mutation scanning tests for over 700 cancer-associated genes and more than 60 validated diagnostic tests to meet the needs of pharmaceutical and biotech companies, research and clinical laboratories, physicians and patients. For more information about the innovative systems, products and services offered by Transgenomic, please visit: http://www.transgenomic.com

Forward-Looking Statement

Certain statements in this press release constitute "forward-looking statements" of Transgenomic within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect to management's current views and estimates of future economic circumstances, industry conditions, company performance and financial results, including the ability of the Company to grow its involvement in the diagnostic products and services markets. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic's reports to the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, e
'/>"/>

SOURCE Transgenomic, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/22/2015)... 22, 2015  Sangamo BioSciences, Inc. (NASDAQ: SGMO ... and accomplishments. For the first quarter ended ... of $5.3 million, or $0.08 per share, compared to ... share, for the same period in 2014. As of ... marketable securities and interest receivable of $226.1 million. ...
(Date:4/22/2015)... , April 22, 2015   MPIRICA Health ... announced $1.6M in Series A financing from the ... funding helps accelerate consumer and employer awareness of ... surgeries at over 4,800 U.S. hospitals. ... are probably very concerned about choosing the hospital ...
(Date:4/22/2015)... April 22, 2015 Steep Hill, the ... today that it has opened an investment round ... and expansion.  The common stock investment round will ... a law intended to encourage funding of small ... 506(c), small businesses largely relied on friends and ...
(Date:4/22/2015)... (PRWEB) April 22, 2015 ... medical devices market witnessed tremendous growth primarily ... and increasing government support with increased nanotechnology ... , Request Customization: , http://www.marketsandmarkets.com/requestCustomization.asp?id=65048077 ... medical devices market is segmented on the ...
Breaking Biology Technology:Sangamo BioSciences Reports First Quarter 2015 Financial Results 2Sangamo BioSciences Reports First Quarter 2015 Financial Results 3Sangamo BioSciences Reports First Quarter 2015 Financial Results 4Sangamo BioSciences Reports First Quarter 2015 Financial Results 5Sangamo BioSciences Reports First Quarter 2015 Financial Results 6Sangamo BioSciences Reports First Quarter 2015 Financial Results 7Sangamo BioSciences Reports First Quarter 2015 Financial Results 8MPIRICA Health Inc. Secures $1.6M to Promote FICO-Like Quality Scores for Surgeries 2Steep Hill Launches $5M Limited Stock Offering 2Steep Hill Launches $5M Limited Stock Offering 3Nanotechnology-based Medical Devices Market to Reach Around $8.5 billion by 2019 - Published by MarketsandMarkets 2Nanotechnology-based Medical Devices Market to Reach Around $8.5 billion by 2019 - Published by MarketsandMarkets 3
... Pharmaceuticals, a,division of Wyeth (NYSE: WYE ... for XYNTHA(TM) Antihemophilic Factor (Recombinant),Plasma/Albumin-Free, a new ... and prevention of bleeding episodes and surgical ... inherited blood-clotting disorder., XYNTHA is produced ...
... Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that that it ... trial using intravenous,administration of REOLYSIN(R) in combination with ... neck cancers. The Principal,Investigator is Dr. Monica Mita ... The University of Texas Health Science Center at ...
... Senior-friendly ,PlanPrescriber, Software Simplifies Medicare - For Free, ... today,announced the latest release of their PlanPrescriber tool. ... worry about whether they are,getting the most out ... MIT Professor Glen Urban, provides users with easy ...
Cached Biology Technology:New Recombinant XYNTHA Now Available for Patients with Hemophilia A 2New Recombinant XYNTHA Now Available for Patients with Hemophilia A 3New Recombinant XYNTHA Now Available for Patients with Hemophilia A 4New Recombinant XYNTHA Now Available for Patients with Hemophilia A 5Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin 2Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin 3On-Line Medicare Advisor Saves Seniors Time, Hassle and Money 2
(Date:4/20/2015)... 2015 Huntington Memorial Hospital is the first ... new miniaturized, wireless monitoring sensor to manage heart failure ... only FDA-approved heart failure monitoring device that has been ... physicians to manage heart failure. The CardioMEMS ... the pulmonary artery (PA) during a non-surgical procedure to ...
(Date:4/14/2015)... 2015  HYPR Corp. today announced it has ... Alliance tm , an industry consortium transforming online ... share technology and collaborate to deliver open specifications ... secure and private, and easier to use. ... protects sensitive user information and eliminates the dependency ...
(Date:4/13/2015)... April 13, 2015  higi, a leading cloud-based consumer ... more fully engage with their communities around health and ... protected and secure API.  ... most accessible, affordable, and convenient vehicle to receive validated ... The API will allow higi,s trusted ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
... MADISON, WI, NOVEMBER 9, 2009 -- ... as a result of their presence in wastes (sewage ... long periods of time. Regulations and guidelines for tolerable ... based on the assumption that the toxic effects of ...
... for use by the U.S. Food and Drug Administration ... growth and invasiveness of ovarian cancer cells and also ... Jonsson Comprehensive Cancer Center found. The drug, when ... in fighting ovarian cancer in cell lines in which ...
... California and elsewhere provide support for the use of ... protecting marine habitats, according to biologists at the University ... in the Gulf of California, for example, confirmed the ... that offspring produced in a protected area can replenish ...
Cached Biology News:Additive copper-zinc interaction affects toxic response in soybean 2FDA approved leukemia drugs shows promise in ovarian cancer cells 2Studies show marine reserves can be an effective tool for managing fisheries 2Studies show marine reserves can be an effective tool for managing fisheries 3Studies show marine reserves can be an effective tool for managing fisheries 4Studies show marine reserves can be an effective tool for managing fisheries 5
... Quidel's depleted sera are specifically depleted ... exception of the depleted protein, the alternative ... reagents are therefore ideal for the detection ... ,Depleted sera have been used to assess ...
... by luciferase-cDNA transfected cell lines has proven ... development of reporter gene assays in which ... for the transcription of other genes. The ... to advantages such as high sensitivity and ...
... is a technique used to reveal two ... Staining Kit is a Zymed polymer double ... simultaneously in the same human cell or ... can be identified using two different primary ...
... the D-2000, but comes with a shutter (controlled ... The D-2000 Deuterium Light Source produces a ... deep-UV versions of the light source are available, ... powerful and stable lamp provides peak-to-peak stability of ...
Biology Products: